Transfer of methadone across the dually perfused preterm human placental lobule

American Journal of Obstetrics and Gynecology

Volumn 198, Issue 1, 2008, Pages 126.e1-126.e4

  Nanovskaya, Tatiana N ^a   Nekhayeva, Ilona A ^b   Hankins, Gary D V ^a   Ahmed, Mahmoud S ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b BELARUSIAN STATE MEDICAL UNIVERSITY   (Belarus)

Author keywords

dual perfusion; methadone; pregnancy; preterm placenta

Indexed keywords

CARBON 14; GLYCOPROTEIN P; METHADONE; PHENAZONE; TRITIUM;

ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG TISSUE LEVEL; FEMALE; FETOMATERNAL TRANSFUSION; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; LIQUID SCINTILLATION COUNTING; PERFUSION; PLACENTA; PLACENTAL TRANSFER; PREMATURITY; PRENATAL DRUG EXPOSURE; PRENATAL PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; TERM BIRTH; TROPHOBLAST;

EID: 37449034584     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2007.06.073     Document Type: Article

References (23)

1. Kaltenbach K., Berghella V., and Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am 25 (1998) 139-151
2. Kandall S.R., Doberczak T.M., Jantunen M., and Stein J. The methadone-maintained pregnancy. Clin Perinatol 26 (1999) 173-183
3. Fisher G., Eder H., Jagsch R., et al. Maintenance therapy with synthetic opioids within a multidisciplinary program-a stabilizing necessity for pregnant opioid dependent females. Arch Women Ment Health 1 (1998) 109-116
4. Jones H.E., Johnson R.E., Jasinski D.R., et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects of the neonatal abstinence syndrome. Drug Alcohol Depend 79 (2005) 1-10
5. Brown H.L., Britton K.A., Mahaffey D., Brizendine E., Hiett A., and Turnquest M.A. Methadone maintenance in pregnancy: a reappraisal. Am J Obstet Gynecol 179 (1998) 459-463
6. Mack G., Thomas D., Giles W., and Buchanan N. Methadone levels and neonatal withdrawal. J Paediatr Child Health 27 (1991) 96-100
7. Berghella V., Lim P.J., Hill M.K., Cherpes J., Chennat J., and Kaltenbach K. Maternal methadone dose and neonatal withdrawal. Am J Obstet Gynecol 189 (2003) 312-317
8. Doberczak T.M., Kandall S.R., and Friedmann P. Relationship between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal. Obstet Gynecol 81 (1993) 936-940
9. Dashe J.S., Sheffield J.S., Olscher D.A., Todd S.J., Jackson G.L., and Wendell G.D. Relationship between maternal methadone dosage and neonatal withdrawal. Obstet Gynecol 100 (2002) 1244-1249
10. Nekhayava I.A., Nanovskaya T.N., Deshmukh S.V., Zharikova O.L., Hankins G.D.V., and Ahmed M.S. Bidirectional transfer of methadone across human placenta. Biochem Pharmacol 69 (2005) 187-197
11. Nanovskaya T.N., Deshmukh S.V., Nekhayeva I.A., Zharikova O.L., Hankins G.D., and Ahmed M.S. Methadone metabolism by human placenta. Biochem Pharmacol 68 (2004) 583-591
12. Nanovskaya T., Nekhayeva I., Karunaratne N., Audus K., Hankins G.D., and Ahmed M.S. Role of P-glycoprotein in transplacental transfer of methadone. Biochem Pharmacol 69 (2005) 1869-1878
13. Miller R.K., Koszalka T.R., and Brent R.L. The transport of molecules across placental membranes. In: Poste G., and Nicolson G.L. (Eds). The cell surface in animal embryogenesis and development. Cell surface review (1976), Elsevier/North-Holland, Inc, Amsterdam-New York-Oxford 145-223
14. Mathias A.A., Hitti J., and Unadkat J.D. P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. Am J Physiol Regul Integr Comp Physiol 289 (2005) 963-969
15. Gil S., Saura R., Forestier F., and Farinotti R. P-glycoprotein expression of the human placenta during pregnancy. Placenta 26 (2005) 268-270
16. Miller R.K., Wier P.J., Zavislan J., et al. Human dual placental perfusions: criteria for toxicity evaluations. In: Heindel J.J., and Chapin R.E. (Eds). Method in toxicology (1993), Academic Press, New York 205-245
17. Bourget P., Roulot C., and Fernandez H. Models for placental transfer studies of drugs. Clin Pharmacokinet 28 (1995) 161-180
18. Nanovskaya T., Deshmukh S., Brooks M., and Ahmed M.S. Transplacental transfer and metabolism of buprenorphine. J Pharmacol Exp Ther 300 (2002) 26-33
19. Smith C.H., Nelson D.M., King B.F., Donohue T.M., Ruzycki S.M., and Kelly L.K. Characterization of a microvillous membrane preparation from human placental syncytiotrophoblast: a morphologic, biochemical and physiologic study. Am J Obstet Gynecol 128 (1977) 190-196
20. Booth A.G., Olayele O., and Oluwaseyi A.V. An improved method for the preparation of human placental syncytiotrophoblast microvilli. Placenta 1 (1980) 327-336
21. Konje J.C., Kaufmann P., Bell S.C., and Taylor D.J. A longitudinal study of quantitative uterine blood flow with the use of color power angiography in appropriate for gestational age pregnancies. Am J Obstet Gynecol 185 (2001) 608-613
22. Bassily M., Ghabrial H., Smallwood R.A., and Morgan D.J. Determinants of placental drug transfer: studies in the isolated perfused human placenta. Pharm Sci 84 (1995) 1054-1060
23. Doberczak T.M., Kandall S.R., and Wilets I. Neonatal opiate abstinence syndrome in term and preterm infants. J Pediatr 118 (1991) 933-937